Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Open label RCT found that tivozanib was superior to sorafenib in terms of progression free survival (5.6 months vs 3.9 months, HR for progression or death 0.73, 95%CI 0.56-0.94), however there was no difference in overall survival (0.97, 0.75-1.24).


European Urology